改进的代谢生物标志物特征区分胰腺导管腺癌与慢性胰腺炎的独立验证与检测标准化
研究在941例患者(胰腺导管腺癌356例、慢性胰腺炎304例、非胰腺疾病281例)中评估单平台单次检测的代谢标志物特征。改进型特征(12种分析物加CA19-9)在识别队列、验证队列1和2中区分胰腺导管腺癌与慢性胰腺炎的曲线下面积分别为97.2%、93.5%和92.2%。简化型特征(4种分析物加CA19-9)在验证队列2中灵敏度77.3%、特异度89.6%、总准确率82.4%,作者认为需进一步大规模评估。
要点
- 简化型代谢特征(4种分析物加CA19-9)单平台单次检测区分胰腺导管腺癌与慢性胰腺炎,验证队列2总准确率82.4%。
- 验证队列2中可切除IA-IIB期胰腺导管腺癌45例,简化型特征灵敏度73.2%、特异度89.6%、准确率82.7%。
- CA19-9低于37 U/mL者简化型特征灵敏度仅39.7%,作者认为该特征需进一步大规模评估。
核心结论
- 单平台单次检测的简化型代谢特征(4种代谢物联合血清CA19-9)是就诊时诊断胰腺导管腺癌的准确诊断工具,作者认为需进一步大规模评估。
研究设计与样本
- 研究纳入941例患者(胰腺导管腺癌356例、慢性胰腺炎304例、非胰腺疾病281例),在3项多中心独立检测中评估识别队列、验证队列1和验证队列2。
- 采用液相色谱-串联质谱平台进行靶向定量血浆代谢物分析,机器学习辅助算法识别改进型与简化型代谢特征并比较性能。
主要发现
- 改进型代谢特征(12种分析物加CA19-9)区分胰腺导管腺癌与慢性胰腺炎的曲线下面积(95%CI)在识别队列为97.2%(97.1%-97.3%)、验证队列1为93.5%(93.4%-93.7%)、验证队列2为92.2%(92.1%-92.3%)。
- 验证队列2中简化型代谢特征(4种分析物加CA19-9)区分胰腺导管腺癌与慢性胰腺炎的灵敏度77.3%、特异度89.6%、总准确率82.4%。
- 验证队列2中45例可切除IA-IIB期胰腺导管腺癌患者,简化型特征灵敏度73.2%、特异度89.6%、准确率82.7%。
- 验证队列2中CA19-9大于2 U/mL的胰腺导管腺癌患者,简化型特征灵敏度81.6%、特异度88.7%、准确率84.5%;CA19-9小于37 U/mL者分别为39.7%、94.1%、76.3%。
关键数值与推荐
- 改进型代谢特征由12种分析物加CA19-9组成;简化型代谢特征由4种分析物加CA19-9组成。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者在结论中提出该简化型代谢特征需进一步大规模评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Pancreatic ductal adenocarcinoma cancer (PDAC) is a highly lethal malignancy requiring efficient detection when the primary tumor is still resectable. We previously developed the MxPancreasScore comprising 9 analytes and serum carbohydrate antigen 19-9 (CA19-9), achieving an accuracy of 90.6%. The necessity for 5 different analytical platforms and multiple analytical runs, however, hindered clinical applicability. We therefore aimed to develop a simpler single-analytical run, single-platform diagnostic signature. METHODS: We evaluated 941 patients (PDAC, 356; chronic pancreatitis [CP], 304; nonpancreatic disease, 281) in 3 multicenter independent tests, and identification (ID) and validation cohort 1 (VD1) and 2 (VD2) were evaluated. Targeted quantitative plasma metabolite analysis was performed on a liquid chromatography-tandem mass spectrometry platform. A machine learning-aided algorithm identified an improved (i-Metabolic) and minimalistic metabolic (m-Metabolic) signatures, and compared them for performance. RESULTS: The i-Metabolic Signature, (12 analytes plus CA19-9) distinguished PDAC from CP with area under the curve (95% confidence interval) of 97.2% (97.1%-97.3%), 93.5% (93.4%-93.7%), and 92.2% (92.1%-92.3%) in the ID, VD1, and VD2 cohorts, respectively. In the VD2 cohort, the m-Metabolic signature (4 analytes plus CA19-9) discriminated PDAC from CP with a sensitivity of 77.3% and specificity of 89.6%, with an overall accuracy of 82.4%. For the subset of 45 patients with PDAC with resectable stages IA-IIB tumors, the sensitivity, specificity, and accuracy were 73.2%, 89.6%, and 82.7%, respectively; for those with detectable CA19-9 >2 U/mL, 81.6%, 88.7%, and 84.5%, respectively; and for those with CA19-9 <37 U/mL, 39.7%, 94.1%, and 76.3%, respectively. CONCLUSIONS: The single-platform, single-run, m-Metabolic signature of just 4 metabolites used in combination with serum CA19-9 levels is an innovative accurate diagnostic tool for PDAC at the time of clinical presentation, warranting further large-scale evaluation.
引用
- Mahajan UM, Oehrle B, Sirtl S, et al. Independent Validation and Assay Standardization of Improved Metabolic Biomarker Signature to Differentiate Pancreatic Ductal Adenocarcinoma From Chronic Pancreatitis. Gastroenterology. 2022. PMID: 35870514. doi:10.1053/j.gastro.2022.07.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。